Evaxion Biotech A/S announced on October 9, 2024, that its AI-Immunology platform has demonstrated strong validation across three different clinical trials. Evidence from trials for personalized cancer vaccine candidates EVX-01, EVX-02, and EVX-03 confirmed the platform's ability to accurately predict vaccine targets.
A statistically significant correlation was observed between the AI-Immunology platform's prediction scores and the immunological responses measured in patients. Vaccine targets with the highest prediction scores generated the most robust immune responses.
Furthermore, in one of the trials where it was assessed, a statistically significant correlation was demonstrated between AI-Immunology prediction scores and Progression Free Survival (PFS) in patients. This finding underscores the platform's capability to identify vaccine targets with meaningful clinical impact.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.